Vitrolife AB (publ) interim report Q2, 2024: Strong Technologies growth and improved margins
Second quarter
- Sales of
SEK 941 (905) million, an increase of 4% in local currencies and 4% in SEK. - Sales per region, in local currencies was -5% in APAC, +11% in EMEA and +5% in
Americas . - Sales growth per business area, in local currencies, was +3% in Consumables, +40% in Technologies and -7% in Genetics.
- Gross margin increased to 59.9% (55.8).
- Operating income before depreciation and amortisation (EBITDA) increased to
SEK 327 (293) million, giving an EBITDA margin of 34.7% (32.4). - Operating cash flow increased to
SEK 236 million (211). - Net income increased to
SEK 143 (106) million, giving earnings per share ofSEK 1.06 (0.78). -
Vitrolife Group acquired the distribution activities of medical devices from EMB, our Iberian distributor. -
Vitrolife Group acquired eFertility (STB Zorg B.V. ).
First half year
- Sales of
SEK 1,782 (1,759) million, an increase of 2% in local currencies and 1% in SEK. - Sales per region, in local currencies was +6% in APAC, +4% in EMEA and -4% in
Americas . - Sales per business area, in local currencies was +8% in Consumables, +23% in Technologies and -10% in Genetics.
- Gross margin increased to 58.6% (56.3).
- Operating income before depreciation and amortisation (EBITDA) increased to
SEK 600 (554) million, giving an EBITDA margin of 33.6% (31.5). - Operating cash flow increased to
SEK 434 million (372). - Net income increased to
SEK 258 (205) million, giving earnings per share ofSEK 1.91 (1.52).
This disclosure contains information that
Contact:
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim report Q2, 2024 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-interim-report-q2-2024-strong-technologies-growth-and-improved-margins-302199066.html
SOURCE